10x Genomics Est. EPS Q/Q
What is the Est. EPS Q/Q of 10x Genomics?
The Est. EPS Q/Q of 10x Genomics, Inc. is 206.67%
What is the definition of Est. EPS Q/Q?
Prospective quarterly EPS growth rate, year over year, is the estimated increase of the company’s EPS for the current quarter compared to performance from a past corresponding quarter.
= current quarter yoy (year over year)
The prospective EPS growth rate is a predicted estimate of the earnings per share growth rate towards the current quarter and expressed as a percentage compared to the respective past quarter. The estimated earnings per share growth rate is an important factor for judging a company's value. Comparing EPS history with stock price history helps determine the most likely future direction of the stock price.
Earnings per share is the monetary value of earnings per outstanding share of common stock for a company. The EPS is usually calculated as profit without preferred dividends divided by weighted average of common stock shares over the past twelve months.
Est. EPS Q/Q of companies in the Health Care sector on NASDAQ compared to 10x Genomics
What does 10x Genomics do?
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell ATAC for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Companies with est. eps q/q similar to 10x Genomics
- Harvest Capital Credit Corp has Est. EPS Q/Q of 200.00%
- Genocea Biosciences Inc has Est. EPS Q/Q of 200.00%
- Fuel Tech Inc has Est. EPS Q/Q of 200.00%
- Intrepid Potash Inc has Est. EPS Q/Q of 205.26%
- Alliance Resource Partners, LP has Est. EPS Q/Q of 206.12%
- Townsquare Media Inc has Est. EPS Q/Q of 206.25%
- 10x Genomics has Est. EPS Q/Q of 206.67%
- American Woodmark has Est. EPS Q/Q of 208.06%
- Sony has Est. EPS Q/Q of 210.00%
- Bonanza Creek Inc has Est. EPS Q/Q of 210.00%
- Beam Therapeutics has Est. EPS Q/Q of 211.90%
- Richards Packaging Income Fund has Est. EPS Q/Q of 212.00%
- Marathon Oil has Est. EPS Q/Q of 212.82%